Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort

Bipolar Disorders

Volumn 18, Issue 3, 2016, Pages 247-260

  Lambert, Christophe G ^a   Mazurie, Aurélien J ^b   Lauve, Nicolas R ^c   Hurwitz, Nathaniel G ^d   Young, S Stanley ^e   Obenchain, Robert L ^f   Hengartner, Nicolas W ^g   Perkins, Douglas J ^a   Tohen, Mauricio ^a   Kerner, Berit ^h  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b MONTANA STATE UNIVERSITY   (United States)

^c MSC01 1070   (United States)

^d New Mexico Behavioral Health Institute   (United States)

^e CGStat LLC   (United States)

^f Risk Benefit Statistics   (United States)

^g LOS ALAMOS NATIONAL LABORATORY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticonvulsants; Antipsychotics; Bipolar disorder; Competing risks; Hypothyroidism; Lithium

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM CARBONATE; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ANTICONVULSIVE AGENT; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT; TRANQUILIZER;

ADULT; AGE; AGED; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; UNITED STATES; CHEMICALLY INDUCED; COMPARATIVE STUDY; RISK; SURVIVAL ANALYSIS;

ADULT; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COHORT STUDIES; FEMALE; HUMANS; HYPOTHYROIDISM; LITHIUM COMPOUNDS; MALE; RISK; SURVIVAL ANALYSIS;

EID: 84969820395     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12391     Document Type: Article

References (94)

1. ®) [Internet]. American Psychiatric Pub, 2013. Available from: http://dx.doi.org/10.1176/appi.books.9780890425596 [accessed April 2015].
2. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617-627.
3. Schou M, Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17: 250-260.
4. Baastrup PC, Schou M. Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 1967; 16: 162-172.
5. Maggs R. Treatment of manic illness with lithium carbonate. Br J Psychiatry. RCP; 1963; 109: 56-65.
6. Goodwin FK, Murphy DL, Bunney WE Jr. Lithium-carbonate treatment in depression and mania. A longitudinal double-blind study. Arch Gen Psychiatry 1969; 21: 486-496.
7. Angst J, Weis P, Grof P, Baastrup PC, Schou M. Lithium prophylaxis in recurrent affective disorders. Br J Psychiatry 1970; 116: 604-614.
8. Baastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 1970; 296: 326-330.
9. Stokes PE, Shamoian CA, Stoll PM, Patton MJ. Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971; 297: 1319-1325.
10. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. American Medical Association; 2000; 57: 481-489.
11. Keck PEJr, McElroy SL. Pharmacological treatments for bipolar disorder. In: Nathan PE, Gorman JM eds. A Guide to Treatments that Work, fourth edition. New York, NY: Oxford University Press, 2015: 273-306.
12. Machado-Vieira R, Manji HK, Zarate CA Jr. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 2009; 11 (Suppl. 2): 92-109.
13. Coppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P, Hermon C. Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord 1991; 23: 1-7.
14. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005;162: 1805-1819.
15. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8: 625-639.
16. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007; 68: 380-383.
17. Johnston AM, Eagles JM. Lithium-associated clinical hypothyroidism. Prevalence and risk factors. Br J Psychiatry 1999; 175: 336-339.
18. Kirov G, Tredget J, John R, Owen MJ, Lazarus JH. A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients. J Affect Disord 2005; 87: 313-317.
19. Henry C. Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. J Psychiatry Neurosci 2002; 27: 104-107.
20. Schou M, Amdisen A, Eskjaer Jensen S, Olsen T. Occurrence of goitre during lithium treatment. Br Med J 1968; 3: 710-713.
21. Rogers MP, Whybrow PC. Clinical hypothyroidism occurring during lithium treatment: two case histories and a review of thyroid function in 19 patients. Am J Psychiatry 1971; 128: 158-163.
22. Candy J. Severe hypothyroidism-an early complication of lithium therapy. Br Med J 1972; 3: 277.
23. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379: 721-728.
24. UpToDate. Lithium: Drug Information [Internet]. 2015. Available from: http://www.uptodate.com/contents/lithium-drug-information [accessed April 2015].
25. Cho JT, Bone S, Dunner DL, Colt E, Fieve RR. The effect of lithium treatment on thyroid function in patients with primary affective disorder. Am J Psychiatry 1979; 136: 115-116.
26. Kuruvilla K, Karunanidhi A, Kanagasabapathy AS. Effects of long-term lithium carbonate treatment on thyroid function in psychiatric patients. Indian J Psychiatry 1983; 25: 98-101.
27. Kupka RW, Nolen WA, Post RM et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 2002; 51: 305-311.
28. Hersh WR, Weiner MG, Embi PJ et al. Caveats for the use of operational electronic health record data in comparative effectiveness research. Med Care 2013; 51 (8 Suppl. 3): S30-S37.
29. Weiskopf NG, Rusanov A, Weng C. Sick patients have more data: the non-random completeness of electronic health records. AMIA Annu Symp Proc 2013; 16: 1472-1477.
30. Rusanov A, Weiskopf NG, Wang S, Weng C. Hidden in plain sight: bias towards sick patients when sampling patients with sufficient electronic health record data for research. BMC Med Inform Decis Mak 2014; 11: 51.
31. Reagan-Udall Foundation for the Food and Drug Administration. Innovation in Medical Evidence Development and Surveillance (IMEDS) Program [Internet]. 2015. Available from: http://www.reaganudall.org/our-work/safety-and-better-evidence/imeds-program/ [accessed April 2015].
32. Regan-Udall Foundation for the Food and Drug Administration. Innovation in Medical Evidence Development and Surveillance (IMEDS) Charter [Internet]. 2013. p. 28-9. Available from: http://www.reaganudall.org/wp-content/uploads/2013/04/RUF_IMEDS_IMEDS-Charter_041813-DRAFT2.pdf [accessed September 2015].
33. Quint JB. Health Research Data for the Real World: The Marketscan Databases. Truven Health Analytics, 2015.
34. Voss EA, Makadia R, Matcho A et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc 2015; 22: 553-564.
35. Liu S, Ma W, Moore R, Ganesan V, Nelson S. RxNorm: prescription for electronic drug information exchange. IT Prof 2005; 7: 17-23.
36. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 2006; 44: 300-303.
37. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-47.
38. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004; 91: 1229-1235.
39. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
40. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika 1982; 69: 553-566.
41. Pepe MS, Mori M. Kaplan-meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993; 12: 737-751.
42. Pintilie M. Competing Risks: A Practical Perspective. West Sussex, England: John Wiley & Sons, 2006.
43. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
44. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010; 45: 1388-1395.
45. Gau C-S, Chang C-J, Tsai F-J, Chao P-F, Gau SS-F. Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: a nested, matched case-control study. Bipolar Disord 2010; 12: 253-263.
46. ® [package insert] [Internet]. AbbVie Inc., 2015. Available from: http://www.rxabbvie.com/pdf/dep3.pdf [accessed January 2016].
47. Ezzaher A, Haj Mouhamed D, Mechri A et al. Thyroid function and lipid profile in bipolar I patients. Asian J Psychiatr 2011; 4: 139-143.
48. Tsui KYQ. The impact of Lithium on thyroid function in Chinese psychiatric population. Thyroid Res 2015; 4: 14.
49. ® [package insert] [Internet]. GlaxoSmithKline. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lamictal/pdf/LAMICTAL-PI-MG.PDF [accessed January 2016].
50. Benedetti MS, Whomsley R, Baltes E, Tonner F. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. Eur J Clin Pharmacol 2005; 61: 863-872.
51. Hamed SA. The effect of antiepileptic drugs on thyroid hormonal function: causes and implications. Expert Rev Clin Pharmacol 2015; 8: 741-750.
52. Post RM, Weiss SRB, Leverich GS, Smith M, Zhang L-X. Sensitization and kindling-like phenomena in bipolar disorder: implications for psychopharmacology. Clin Neurosci Res 2001; 1: 69-81.
53. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 2007; 31: 858-873.
54. Wiglusz MS, Landowski J, Cubała WJ, Agius M. Overlapping phenomena of bipolar disorder and epilepsy-a common pharmacological pathway. Psychiatr Danub 2015; 27 (Suppl. 1): S177-S181.
55. Knott S, Forty L, Craddock N, Thomas RH. Epilepsy and bipolar disorder. Epilepsy Behav. 2015; 52 (Pt A): 267-274.
56. Tamijani SMS, Karimi B, Amini E et al. Thyroid hormones: possible roles in epilepsy pathology. Seizure 2015; 31: 155-164.
57. Aggarwal A, Rastogi N, Mittal H, Chillar N, Patil R. Thyroid hormone levels in children receiving carbamazepine or valproate. Pediatr Neurol 2011; 45: 159-162.
58. Kim SH, Chung HR, Kim SH et al. Subclinical hypothyroidism during valproic acid therapy in children and adolescents with epilepsy. Neuropediatrics 2012; 43: 135-139.
59. Lai EC-C, Yang Y-HK, Lin S-J, Hsieh C-Y. Use of antiepileptic drugs and risk of hypothyroidism. Pharmacoepidemiol Drug Saf. 2013; 22: 1071-1079.
60. Verrotti A, Scardapane A, Manco R, Chiarelli F. Antiepileptic drugs and thyroid function. J Pediatr Endocrinol Metab 2008; 21: 401-408.
61. ® [package insert] [Internet]. Novartis Pharmaceuticals Corporation, 2015. Available from: https://www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf [accessed January 2016].
62. ® [package insert] [Internet]. Novartis Pharmaceuticals Corporation, 2014. Available from: https://www.pharma.us.novartis.com/product/pi/pdf/trileptal.pdf [accessed January 2016 ].
63. Miller J, Carney P. Central hypothyroidism with oxcarbazepine therapy. Pediatr Neurol 2006; 34: 242-244.
64. Lania A, Persani L, Beck-Peccoz P. Central hypothyroidism. Pituitary 2008; 11: 181-186.
65. Feret BM, Caley CF. Possible hypothyroidism associated with quetiapine. Ann Pharmacother 2000; 34: 483-486.
66. Ramaswamy S, Siddiqui Z, Saharan S, Gabel TL, Bhatia SC. Quetiapine-induced hypothyroidism. J Psychiatry Neurosci 2005; 30: 57.
67. Greenspan A, Gharabawi G, Kwentus J. Thyroid dysfunction during treatment with atypical antipsychotics. J Clin Psychiatry 2005; 66: 1334-1335.
68. Liappas J, Paparrigopoulos T, Mourikis I, Soldatos C. Hypothyroidism induced by quetiapine: a case report. J Clin Psychopharmacol 2006; 26: 208-209.
69. Kontaxakis V, Karaiskos D, Havaki-Kontaxaki B et al. P03-10 Quetiapine and hypothyroidism: a literature review. Eur Psychiatry 2009; 24 (Suppl. 1): S1009.
70. Poutanen O, Iso-Koivisto E, Työläjärvi M, Leinonen E. Quetiapine-associated hypothyroidism in young female patients: a report of three cases. Pharmacopsychiatry 2010; 43: 237-239.
71. Findling RL, Pathak S, Earley WR, Liu S, DelBello MP. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2014; 24: 325-335.
72. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41: 1216-1223.
73. Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 2005; 66: 80-84.
74. Kontaxakis VP, Karaiskos D, Havaki-Kontaxaki BJ, Ferentinos P, Papadimitriou GN. Can quetiapine-induced hypothyroidism be reversible without quetiapine discontinuation? Clin Neuropharmacol 2009; 32: 295-296.
75. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B; Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166: 476-488.
76. Park Y-M, Kang S-G, Lee B-H, Lee H-J. Decreased thyroid function in Korean women with bipolar disorder receiving valproic acid. Gen Hosp Psychiatry. 2011; 33: 200.e13-200.e15.
77. Seroquel XR® [package insert] [Internet]. AstraZeneca Pharmaceuticals LP, 2013. Available from: http://www.azpicentral.com/seroquel-xr/seroquelxr.pdf [accessed January 2016].
78. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther 2010; 32 (Suppl. 1): S3-S20.
79. Church CO, Callen EC. Myxedema coma associated with combination aripiprazole and sertraline therapy. Ann Pharmacother 2009; 43: 2113-2116.
80. Zyprexa® [package insert] [Internet]. Eli Lilly and Company, 2015. Available from: http://pi.lilly.com/us/zyprexa-pi.pdf [accessed January 2016].
81. Risperdal® [package insert] [Internet]. Janssen Pharmaceuticals, Inc., 2014. Available from: http://www.janssen.com/us/sites/www_janssen_com_usa/files/products-documents/risperdal.pdf [accessed January 2016].
82. Abilify® [package insert] [Internet]. Bristol-Myers Squibb Company, 2014. Available from: http://packageinserts.bms.com/pi/pi_abilify.pdf [accessed January 2016].
83. Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. CNS Drugs 2009; 23: 1003-1021.
84. Kleiner J, Altshuler L, Hendrick V, Hershman JM. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J Clin Psychiatry 1999; 60: 249-255.
85. Fagiolini A, Kupfer DJ, Scott J et al. Hypothyroidism in patients with bipolar I disorder treated primarily with lithium. Epidemiol Psichiatr Soc 2006; 15: 123-127.
86. Zarate CA, Tohen M, Zarate SB. Thyroid function tests in first-episode bipolar disorder manic and mixed types. Biol Psychiatry 1997; 42: 302-304.
87. Lithobid® [package insert] [Internet]. Noven Therapeutics, LLC, 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018027s056lbl.pdf [accessed January 2016].
88. Valle J, Ayuso-Gutierrez JL, Abril A, Ayuso-Mateos JL. Evaluation of thyroid function in lithium-naive bipolar patients. Eur Psychiatry 1999; 14: 341-345.
89. Kraszewska A, Chlopocka-Wozniak M, Abramowicz M, Sowinski J, Rybakowski JK. A cross-sectional study of thyroid function in 66 patients with bipolar disorder receiving lithium for 10-44 years. Bipolar Disord 2015; 17: 375-380.
90. Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 1998; 8: 909-913.
91. Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23: 723-733.
92. Vonk R, van der Schot AC, Kahn RS, Nolen WA, Drexhage HA. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol Psychiatry 2007; 62: 135-140.
93. Bauer M, Glenn T, Pilhatsch M, Pfennig A, Whybrow PC. Gender differences in thyroid system function: relevance to bipolar disorder and its treatment. Bipolar Disord 2014; 16: 58-71.
94. Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 2015; 386: 461-468.